卵巢癌：邁向分子標的治療的時代 是由出版商Datamonitor在2010年07月所出版的。
這份英文市場調查報告書包含Pages: 93 價格從美金3800起跳。
卵巢癌患者為數眾多，不幸的是仍有各種無藥可醫的症狀，因此成為研究開發的主要對象。期待未來由分子標的療法改善患者的狀況。
本報告書彙整了卵巢癌的概要與無藥可醫症狀的介紹、目前的療法與各種議論、後期生產線的概要介紹，以及利益關係者的見解等，內容概要摘記如下。
概要
重點摘要
患者概要
- 主要的調查結果
- 定義
- 疾病學
- 全球7大市場中，卵巢癌患者數將在2019年之前達到63,000人的規模
- 北歐各國罹患卵巢癌的機率最高
- 目前的治療方法
- 無藥可醫症狀
- 希冀有療效更佳的藥劑治療發病中的癌症病患
- 有效的篩檢將大幅提升患者的生存率
- 研究開發以分子標的療法為主要對象
- 早期患者應以低侵蝕性的外科手術為主
市場潛能
生產線分析
- 主要的調查結果
- 卵巣癌的生產線概要
- 卵巣癌後期的生產線
- Avastin
- Karenitecin
- Opaxio
- Paclical
- Tarceva
- Vargatef
- Votrient
- Farletuzumab
- Abagovomab
參考資訊
附錄
Abstract
Introduction
Despite advances in the management of the disease, outcomes remain poor for
patients with advanced epithelial ovarian cancer. The high level of unmet
need, coupled with the large size of the patient population, is driving
extensive R&D interest in this indication. The anticipated incorporation of
molecular targeted therapies into treatment is expected to improve patient
outcomes in the future.
Scope
- Ovarian cancer overview, including disease definition, epidemiology,
discussion of unmet needs, and market potential
- Current treatment options for ovarian cancer and ongoing controversies
- Examination of the late-phase ovarian cancer pipeline, including drug
profiles of late-stage agents
- Stakeholder opinions based on qualitative interviews with key opinion
leaders from the US and EU
Highlights
Ovarian cancer is the leading cause of death from gynecological malignancies
in the Western world. This is because the majority of epithelial ovarian
cancer patients present with advanced disease at diagnosis, where treatment
has a palliative rather than curative intent.
While first-line platinum-based chemotherapy can result in high response rates
of over 70-80%, the majority of patients will advanced epithelial ovarian
cancer will eventually relapse with incurable disease. As such, there is a
need for novel first-line therapies to improve survival rates.
R&D interest in ovarian cancer is high. There are currently 85 drugs in the
pipeline, which is dominated by molecular targeted therapies (42%) and
cytotoxic therapies (33%). Competition for the approval of the first molecular
targeted therapy in ovarian cancer is fierce.
Reasons to Purchase
- Estimate the number of treatable patients and identify unmet needs for
future drug development opportunities
- Understand the current treatment of the disease, as well as opportunities
and threats in the ovarian cancer market
- Analyze the current ovarian cancer pipeline and the potential of
late-stage drugs
Table of Contents
Overview
- Catalyst
- Summary
- About Datamonitor healthcare
- About the Oncology pharmaceutical analysis team
Executive Summary
- Scope of the analysis
- Datamonitor insight into the ovarian cancer market
- Related reports
- Upcoming reports
- Table of Contents
Patient Potential
- Key findings
- Definition
- Epithelial tumors
- The vast majority of ovarian cancers are epithelial in origin
- The majority of epithelial ovarian cancers are sporadic in nature
- Germ cell tumors
- Sex cord-stromal tumors
- A successful screening test for ovarian cancer has not been developed
- Ovarian cancer is a surgically staged malignancy
- Epidemiology
- The incidence of ovarian cancer in the seven major markets is forecast to
reach nearly 63,000 cases by 2019
- The highest ovarian cancer rates prevail in Northern European countries
- Current treatment options
- Most early-stage patients are treated with surgery and chemotherapy
- Surgery has a central role in the management of advanced disease
- First-line platinum-based chemotherapy is the standard of care for
advanced disease
- The use of intraperitoneal chemotherapy remains controversial
- Maintenance therapy has not been shown to improve overall survival
- The treatment of recurrent disease is rarely curative and depends on
patients' platinum sensitivity
- Platinum-based combination chemotherapy is recommended for
platinum-sensitive recurrent disease
- A number of single agents can be used in the treatment of
platinum-resistant recurrent disease
- Unmet need
- More effective agents are required for the treatment of advanced disease
- An effective screening test could significantly improve patient survival
- R&D efforts should be directed towards molecular targeted therapies
- Less invasive surgical approaches should be explored for early-stage
patients
Market potential
- Key findings
- Current market overview
- Opportunities and threats
- Opportunities
- Significant unmet need remains in the treatment of advanced disease
- There is increased interest in the development of molecular targeted
therapies
- There is a large patient base in ovarian cancer, and a high commercial
attractiveness
- Threats
- The development of an effective screening modality could decrease the
patient base
Pipeline Analysis
- Key findings
- Ovarian cancer pipeline overview
- Ovarian cancer late-phase pipeline
- Avastin (bevacizumab; Genentech/Roche/Chugai)
- Drug profile
- Development overview
- Product positioning
- SWOT analysis
- Karenitecin (cositecan; BNP-1350; BioNumerik)
- Drug profile
- Development overview
- Product positioning
- SWOT analysis
- Opaxio (paclitaxel poliglumex; Cell Therapeutics/Novartis)
- Drug profile
- Development overview
- Product positioning
- SWOT analysis
- Paclical (micellar paclitaxel formulation; Oasmia)
- Drug profile
- Development overview
- Product positioning
- SWOT analysis
- Tarceva (erlotinib; Genentech/Roche/Chugai/OSI)
- Drug profile
- Development overview
- Product positioning
- SWOT analysis
- Vargatef (intedanib; BIBF-1120; Boehringer Ingelheim)
- Drug profile
- Development overview
- Product positioning
- SWOT analysis
- Votrient (pazopanib; GlaxoSmithKline)
- Drug profile
- Development overview
- Product positioning
- SWOT analysis
- Farletuzumab (MORAb-003; Morphotek/Eisai)
- Drug profile
- Development overview
- Product positioning
- SWOT analysis
- Abagovomab (Menarini/Cell Control Biomedical)
- Drug profile
- Development overview
- Product positioning
- SWOT analysis
Bibliography
- Journals
- Websites
- Datamonitor reports
Appendix
- Contributing experts
- Report methodology
- About Datamonitor
- About Datamonitor Healthcare
- About the Oncology analysis team
- Disclaimer
List of Tables
- Table 1: Staging of ovarian cancer using the International Federation of
Gynecology and Obstetrics (FIGO) and American Joint Committee on Cancer (AJCC)
classification
- Table 2: Crude incidence rates of ovarian cancer per 100,000 population in
the seven major pharmaceutical markets, 2002
- Table 3: Forecast incidence of ovarian cancer in the seven major
pharmaceutical markets, 2002-2019
- Table 4: Top 5 countries with the highest crude incidence rates of ovarian
cancer, 2002
- Table 5: Survival results for randomized Phase III trials comparing
cisplatin-paclitaxel with carboplatin-paclitaxel in advanced ovarian cancer
- Table 6: Survival and selected toxicity results for randomized Phase III
trial comparing docetaxel-carboplatin versus paclitaxel-carboplatin in ovarian
cancer
- Table 7: Randomized trials in platinum-sensitive ovarian cancer
- Table 8: Selected clinical trial results for Yondelis presented at the
American Society of Clinical Oncology (ASCO) meeting, June 2010
- Table 9: Drugs approved by the US Food & Drug Administration (FDA) for the
treatment of ovarian cancer
- Table 10: Pipeline agents in Phase III development for ovarian cancer, 2010
- Table 11: Pipeline agents in Phase II development for ovarian cancer, 2010
- Table 12: Pipeline agents in Phase I development for ovarian cancer, 2010
- Table 13: Avastin - drug profile, 2010
- Table 14: Ongoing Phase III clinical trials for Avastin in ovarian cancer,
2010
- Table 15: Selected Phase II trials of Avastin in ovarian cancer
- Table 16: Karenitecin - drug profile, 2010
- Table 17: Ongoing clinical trials for Karenitecin in ovarian cancer, 2010
- Table 18: Phase II results for Karenitecin in the third-line treatment of
recurrent or persistent platinum-resistant epithelial ovarian or primary
peritoneal cancer
- Table 19: Opaxio - drug profile, 2010
- Table 20: Ongoing clinical trials for Opaxio in ovarian cancer, 2010
- Table 21: Paclical - drug profile, 2010
- Table 22: Ongoing clinical trials for Paclical in ovarian cancer, 2010
- Table 23: Tarceva - drug profile, 2010
- Table 24: Ongoing clinical trials for Tarceva in ovarian cancer, 2010
- Table 25: Clinical trial results for Tarceva maintenance therapy in
ovarian cancer
- Table 26: Vargatef - drug profile, 2010
- Table 27: Ongoing clinical trials for Vargatef in ovarian cancer, 2010
- Table 28: Phase II results for Vargatef as maintenance therapy in advanced
ovarian cancer
- Table 29: Votrient - drug profile, 2010
- Table 30: Ongoing clinical trials for Votrient in ovarian cancer, 2010
- Table 31: Phase II results for Votrient maintenance therapy in epithelial
ovarian, fallopian tube or primary peritoneal cancer patients with a rising CA
125 level following first- or second-line therapy
- Table 32: Farletuzumab - drug profile, 2010
- Table 33: Ongoing clinical trials for farletuzumab in ovarian cancer, 2010
- Table 34: Results of a Phase II study evaluating farletuzumab in
platinum-sensitive ovarian cancer at first relapse, 2010
- Table 35: Abagovomab - drug profile, 2010
- Table 36: Ongoing clinical trials for abagovomab in ovarian cancer, 2010
- Table 37: Phase I/II results for abagovomab as maintenance therapy in
recurrent ovarian cancer
List of Figures
- Figure 1: Cellular origin of the three main types of ovarian cancer
- Figure 2: Stage distribution and corresponding 5-year survival rate for
ovarian cancer in the US, 1999-2005
- Figure 3: Forecast incidence and mortality of ovarian cancer in 2010 and
2019 across the seven major pharmaceutical markets
- Figure 4: Forecast incidence of ovarian cancer in Brazil, Russia, India,
and China, 2010 and 2019
- Figure 5: Key unmet needs in ovarian cancer, 2010
- Figure 6: Number of drugs in development for ovarian cancer by phase of
development, 2010
- Figure 7: Ovarian cancer pipeline by type of therapy, 2010
- Figure 8: Ovarian cancer late-phase pipeline by type of therapy, 2010
- Figure 9: Avastin - SWOT analysis in ovarian cancer, 2010
- Figure 10: Karenitecin - SWOT analysis in ovarian cancer, 2010
- Figure 11: Opaxio - SWOT analysis in ovarian cancer, 2010
- Figure 12: Paclical - SWOT analysis in ovarian cancer, 2010
- Figure 13: Tarceva - SWOT analysis in ovarian cancer, 2010
- Figure 14: Vargatef - SWOT analysis in ovarian cancer, 2010
- Figure 15: Phase II trial design for Votrient maintenance therapy in
epithelial ovarian, fallopian tube or primary peritoneal cancer patients with
a rising CA 125 level following first- or second-line therapy
- Figure 16: Votrient - SWOT analysis in ovarian cancer, 2010
- Figure 17: Design of a Phase II study evaluating farletuzumab in
platinum-sensitive ovarian cancer at first relapse
- Figure 18: Farletuzumab - SWOT analysis in ovarian cancer, 2010
- Figure 19: Abagovomab - SWOT analysis in ovarian cancer, 2010
|
